Puerarin Encyclopedia — Scientific Background

What Is Puerarin?

Puerarin (CAS 3681-99-0), also known as Kakonein, is an isoflavone C-glucoside (8-β-D-glucopyranosyl-4′,7-dihydroxyisoflavone) and the principal bioactive compound of kudzu root (Pueraria lobata). It is a member of the isoflavonoid C-glycosides class, characterized by a glucose moiety attached directly to the isoflavone backbone via a carbon-carbon bond—a structural feature that distinguishes it from common O-glycosyl isoflavones and contributes to its unique metabolic stability.

Botanical Source

Puerarin is extracted from the dried root of Pueraria lobata (Willd.) Ohwi or Pueraria thomsonii Benth., commonly known as kudzu or Gegen. Kudzu is a perennial climbing vine native to East Asia and has been used in traditional Chinese medicine for centuries. The root is the primary medicinal part and contains the highest concentration of puerarin. Commercial puerarin is produced through hydroalcoholic extraction and purification, with standardized grades ranging from 15% to 98% purity.

Mechanisms of Action

Antioxidant Defense

Puerarin acts as an intracellular reactive oxygen species (ROS) scavenger and has been characterized as an autophagy inducer and ferroptosis inhibitor. It protects cells from oxidative damage caused by a variety of toxic stimuli, including hydrogen peroxide, glutamate, and β-amyloid peptides.

Anti-Inflammatory Activity

Puerarin modulates inflammatory responses by inhibiting key inflammatory signaling pathways. It has demonstrated anti-inflammatory activity in various experimental models, reducing the production of pro-inflammatory cytokines and mediators.

Cardiovascular Protection

Puerarin is a recognized cardioprotective agent. It increases cerebral and coronary blood flow, reduces vascular resistance, and improves microcirculation. Clinical studies have evaluated puerarin for the treatment of coronary heart disease, angina, myocardial infarction, and retinal vascular disorders. A pharmacokinetic study using mitochondria-targeted puerarin-loaded liposomes demonstrated effective delivery to ischemic myocardium and improvement in reducing myocardial ischemia/reperfusion injury.

Neuroprotective Effects

Puerarin protects hippocampal neurons from β-amyloid-induced neurotoxicity, a hallmark of Alzheimer‘s disease pathology. In vitro studies demonstrate that puerarin protects different cell types from damage caused by various toxic stimuli, including hydrogen peroxide, glutamate, zinc, and copper/cysteine. Borneol-modified puerarin liposomes have been developed to enhance brain tissue distribution for cerebral ischemia treatment.

Metabolic Regulation

Puerarin exhibits hypoglycemic and lipid-lowering activities. In animal studies, oral administration of puerarin (300 mg/kg/day) to rats on a high-cholesterol diet significantly reduced serum and hepatic total cholesterol levels. Clinical trials are evaluating puerarin for metabolic-associated fatty liver disease (MAFLD), with a primary outcome measure of liver fat content changes assessed by MRI-proton density fat fraction.

5-HT2C Receptor Antagonism

Puerarin acts as a 5-HT2C receptor antagonist and a benzodiazepine site antagonist. This mechanism underlies its investigation for the treatment of alcohol abuse and its potential effects on mood and appetite regulation.

The Bioavailability Challenge

Despite its broad pharmacological potential, puerarin presents significant formulation challenges. The compound has poor water solubility and low intestinal permeability. Following oral administration, puerarin undergoes rapid metabolism and elimination, with an elimination half-life of approximately 1.5–2 hours. These factors result in low oral bioavailability and limit its clinical utility.

liposomal encapsulation addresses these limitations through a biomimetic phospholipid bilayer that protects puerarin during digestive transit, prevents premature metabolism, and provides sustained release kinetics. A pharmacokinetic study in rats demonstrated that liposomal puerarin achieved a relative bioavailability of 168% compared to puerarin solution. A separate study using puerarin proliposomes in humans reported a relative bioavailability of 145.6% compared to conventional tablets, with a higher peak plasma concentration (Cmax 1.12 ± 0.21 mg/L vs 0.98 ± 0.17 mg/L) and reduced clearance (CL 10.1 ± 2.2 L/h vs 16.5 ± 4.6 L/h).

Liposomal Puerarin

Liposomal encapsulation of puerarin provides an additional layer of protection and delivery enhancement beyond the isoflavone itself. The phospholipid bilayer surrounds the puerarin molecule, forming a shield that protects it from premature metabolism and enzymatic degradation in the gastrointestinal tract. This delivery system:

• Protects puerarin from rapid metabolism and elimination

• Enhances cellular uptake through membrane fusion

• Supports sustained release and prolonged circulation time

• Improves oral bioavailability significantly compared to free puerarin

Optimized liposomal puerarin formulations achieve encapsulation efficiency of approximately 70.56% with drug loading efficiency of 9.20% and an average particle size of 127.20 nm. Advanced formulations including long-circulating liposomes and targeted liposomes have demonstrated enhanced therapeutic efficacy in preclinical models of osteoporosis, myocardial ischemia, and cerebral ischemia.

Safety and Regulatory

Puerarin is generally well tolerated. Clinical studies using oral puerarin supplementation at 90.2–180 mg per day for 12 weeks have reported no serious adverse events. Puerarin is widely commercialized as a dietary supplement ingredient and pharmaceutical agent. In the United States, puerarin is available as a dietary supplement. In China, puerarin injections and oral formulations are approved for clinical use. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

299$/KG

239$/KG